ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CDY Cellmid Limited

0.056
0.00 (0.00%)
12 May 2024 - Closed
Delayed by 20 minutes
Share Name Share Symbol Market Type
Cellmid Limited ASX:CDY Australian Stock Exchange Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.056 0.056 0.058 0.00 01:00:00

Vista Partners Updates Coverage on Cellmid Limited; Raises Target Price to AUD $0.12

16/11/2011 8:12pm

PR Newswire (US)


Cellmid (ASX:CDY)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Cellmid Charts.

SAN FRANCISCO, Nov. 16, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Cellmid Ltd. (ASX: CDY) (the "Company") and raised its twelve month target price to AUD $0.12. Ross Silver, Principal Analyst at Vista Partners stated, "Cellmid is on track to enter clinical trials for its AMI indication with a market estimated to be in the billions. The Company recently completed humanisation of its "first in class" anti-midkine antibody, hu91, in collaboration with Antitope Ltd. The humanisation has been completed on time and within budget and resulted in a drug that can enter clinical development. This is the most significant milestone to date in the Company's antibody program and has removed a substantial risk from the clinical development path." Mr. Silver continued, "Cellmid has a large portfolio of patents surrounding midkine and owns 21 patent families worldwide. Cellmid plans to monetize this portfolio through two segments: Diagnostics and Therapeutics. The Diagnostic programs are in a more advanced stage and are poised to face regulatory approvals first. The Therapeutic programs are in pre-clinical trials; however they involve high value antibody candidates with early partner/licensing potential."

To download a FREE copy of the Cellmid Ltd. research report, please visit www.vistapglobal.com and complete the research form to gain access to the report.  

About Vista Partners:

Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Disclaimer & Disclosure:

For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.

Contact:

877.215.4813 or info@vistapglobal.com

SOURCE Vista Partners

Copyright 2011 PR Newswire

1 Year Cellmid Chart

1 Year Cellmid Chart

1 Month Cellmid Chart

1 Month Cellmid Chart

Your Recent History

Delayed Upgrade Clock